{"analyses":[{"ciLowerLimit":"0.603","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.983","groupDescription":"Hazard ratio (A+AVD/ABVD) and 95% confidence interval (CI) are based on a stratified Cox's proportional hazard regression model with stratification factors region and number of International Prognostic Factor Project (IPFP) risk factors at baseline with treatment as the explanatory variable in the model. Hazard ratio less than (\\<) 1 favors A+AVD arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.035","paramType":"Hazard Ratio (HR)","paramValue":"0.770","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Median and confidence interval was not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"48.2","upperLimit":"NA","value":"NA"},{"comment":"Median and confidence interval was not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"664"},{"groupId":"OG001","value":"670"}],"units":"Participants"}],"description":"mPFS was defined as the time from the date of randomization to the date of the first of documentation of progressive disease (PD), death due to any cause, or for participants who were confirmed non complete responders per IRF, receipt of subsequent anticancer therapy for Hodgkin lymphoma (HL) after completion of frontline therapy. PD was defined as any new lesion or increase by greater than or equal to (\\>=) 50 percent (%) of previously involved sites from nadir. Frontline therapy is the part of standard set of treatments.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.","id":"OG000","title":"A+AVD"},{"description":"Doxorubicin 25 mg/m\\^2, bleomycin 10 units per square meter (units/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.","id":"OG001","title":"ABVD"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all participants randomized to treatment.","reportingStatus":"POSTED","timeFrame":"Baseline until PD or death or receipt of any subsequent anticancer therapy for HL after completion of frontline therapy (approximately up to 4 years)","title":"Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF)","type":"PRIMARY","unitOfMeasure":"months"}